Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 311 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Overweight Subjects Clear all

Conditions: Abdominal Obesity
Interventions: STP705; Drug
Lead sponsor: Sirnaomics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: NNC9204-1177 A 1.0 mg/mL, PLACEBO; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Obesity, Overweight
Interventions: Tirzepatide, Placebo, Liraglutide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Indianapolis, Indiana • Baton Rouge, Louisiana • Baltimore, Maryland

Conditions: Obesity, Insulin Resistance
Interventions: Fenretinide, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2099
U.S. locations: 1
States / cities: San Diego, California

Conditions: Asthma
Interventions: Seeking Health Probiota Bifido; Dietary Supplement
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 99 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Obesity
Interventions: IHBG-10, Placebo; Dietary Supplement
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Heart Failure, Obesity, Weight Loss, Heart Failure With Preserved Ejection Fraction
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: Gastric bypass for diabetic patients <35 BMI; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity
Interventions: ERX1000, Placebo; Drug
Lead sponsor: ERX Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Weight Loss
Interventions: VK2735, Placebo; Biological
Lead sponsor: Viking Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 20
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more

Conditions: Liver Diseases
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Obesity
Interventions: Liraglutide, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Obese, Obesity
Interventions: HM15275, Placebo of HM15275; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 14
States / cities: Chula Vista, California • Oak Lawn, Illinois • Ames, Iowa + 10 more

Conditions: Obesity, Overweight
Interventions: Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Placebo, Ancillary therapy; Drug · Behavioral
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,742 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 34
States / cities: Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 28 more

Conditions: Prader-Willi Syndrome
Interventions: Placebo, Tesomet; Other · Drug
Lead sponsor: Saniona; Industry
Eligibility: 13 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Non-diabetic Overweight or Obese
Interventions: BGM0504, Placebo; Drug
Lead sponsor: BrightGene Bio-Medical Technology Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: Aramchol free acid, Placebo; Drug
Lead sponsor: Galmed Research and Development, Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Miami, Florida • Arlington, Texas

Conditions: Obesity
Interventions: ReShape Duo balloon, Diet counseling, Exercise counseling; Device · Other
Lead sponsor: ReShape Lifesciences; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 8
States / cities: Scottsdale, Arizona • Dalton, Georgia • Marquette, Michigan + 5 more

Conditions: Obesity
Interventions: CP-945,598; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Obesity
Interventions: Betahistine, Dietary counseling; Drug · Behavioral
Lead sponsor: OBEcure Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 19
States / cities: Birmingham, Alabama • San Diego, California • Walnut Creek, California + 14 more

Conditions: Insulin Resistance
Interventions: HE3286; Drug
Lead sponsor: Harbor Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Hepatitis C
Interventions: Pioglitazone, Prednisone; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 5
States / cities: Santa Monica, California • Baltimore, Maryland • Buffalo, New York + 2 more

Conditions: Obesity
Interventions: HM11260C, Placebo; Biological
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 297 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

A Study to Evaluate Safety, Tolerability of Subcutaneous Injection in Adult Subjects Undergoing Abdominoplasty

Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity

A Study of Tirzepatide in Overweight and Very Overweight Participants

A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity

Oral Probiotic Administration to Modulate the Airway Microbiome in Obese Asthmatic Subjects

Anti-psychotic Medication (New Use) Weight Loss Study

WeighT LOSS Surgery and Comprehensive Cardiometabolic Responses to to EXercise

Laparoscopic Gastric Bypass for Type 2 Diabetes Mellitus With Body Mass Index (BMI) < 35

ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

VK2735 for Weight Management Phase 2

Magnetic Resonance Spectroscopy (MRS) Validation Study in Individuals With Nonalcoholic Fatty Liver Disease (NAFLD)

Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects

A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)

A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Duo™ Intragastric Balloon System in Obese Subjects

Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics

The Effect of Betahistine on Body Weight in Obese Subjects

A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production

Study the Relationship Between Obesity and Hepatitis C Replication

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

Effect of LAPS-Exendin on Body Weight in Obese Population